RxDoctor Payments Data

Cherry Chandi, MD

Internal Medicine · Highland Village, TXNPI 1265425664

Payments from drug & device makers

$3,702in general payments, 2019–2025

Across 138 payments — averaging $26.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$919
  • AstraZeneca$478
  • Amgen$354
  • Novo Nordisk$296
  • Esperion Therapeutics, Inc.$247
  • GSK$241
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,65499%
  • Education$481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,702 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$116,096
Medicare patients
157
Services billed
1,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$95,181
MounjaroTirzepatide78$89,523
EliquisApixaban26$31,927
ProliaDenosumab16$27,279
JardianceEmpagliflozin21$25,824
Tresiba Flextouch U-100Insulin Degludec11$6,514
Rosuvastatin Calcium305$4,028
Atorvastatin Calcium403$2,972
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,867
Levothyroxine Sodium371$2,855
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$2,323
Metoprolol Succinate142$1,993
Ezetimibe86$1,972
Omeprazole153$1,731
Nano 2nd Gen Pen NeedlePen Needle, Diabetic11$1,701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$296$95,18189 claims
Lilly USA, LLCMounjaro$76$89,52378 claims
PfizerEliquis$110$31,92726 claims
AmgenProlia$354$27,27916 claims
Boehringer IngelheimJardiance$919$25,82421 claims
AbbVieSynthroid$63$91532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Highland Village

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →